The humanistic burden of Pompe disease: are there still unmet needs? A systematic review
- PMID: 29166883
- PMCID: PMC5700516
- DOI: 10.1186/s12883-017-0983-2
The humanistic burden of Pompe disease: are there still unmet needs? A systematic review
Abstract
Background: Humanistic burden considers the impact of an illness on a patient's health-related quality of life (HRQoL), activities of daily living (ADL), caregiver health, and caregiver QoL. Humanistic burden also considers treatment satisfaction and adherence to treatment regimens. Pompe disease is an autosomal recessive, progressive, multisystemic neuromuscular disease. Approval of enzyme-replacement therapy (ERT) markedly improved prognosis for patients, but considerable morbidity and a substantial humanistic burden remain. This article characterizes the humanistic burden of Pompe disease through a systematic literature review.
Methods: A systematic search of MEDLINE® and Embase® with back-referencing and supplementary literature searches was performed to retrieve data from interventional and non-interventional studies on the humanistic burden of Pompe disease. Publications were screened according to predefined criteria, extracted, and assessed for quality. Extracted data were narratively synthesized.
Results: No publications on the humanistic burden of infantile-onset Pompe disease (IOPD) were identified. As such, of 17 publications included here, all are in patients with late-onset Pompe disease (LOPD). Thirteen publications were initiated after approval of ERT, two were initiated before, and two overlapped the approval of ERT. The review shows that LOPD patients have a significantly lower HRQoL than the general population, even if treated with ERT. On transitioning to ERT, treatment was associated with improvement in the physical component score of the SF-36 and fatigue, although the SF-36 mental component score remained stable. Physical HRQoL remained below population norms after 4 years of ERT. Significantly more ERT-treated patients reported pain than controls, and bodily pain worsened in later years following ERT initiation. Treatment-naïve LOPD patients had significantly poorer ADL functioning compared with the general population, although ERT stabilized deteriorating functioning impairment. ERT studies showed caregivers provide 17.7 h/week informal care on average. Fifty percent, 40% and <20% of caregivers reported mental health, physical health, and financial/relational problems, respectively. In ERT-naïve patients, wheelchair use and home ventilatory support was associated with lower physical HRQoL and ADL functioning. In ERT-treated patients, key factors predicting worse HRQoL and ADL functioning were higher respiratory distress, poorer sleep quality, greater pain, and more fatigue.
Conclusions: Pompe disease has a substantial humanistic burden, with strong inter-relationships among and between humanistic burden parameters and clinical progression.
Keywords: Caregiver burden; Daily living; Humanistic burden; Pompe; Quality of life.
Conflict of interest statement
Ethics approval and consent to participate
Not applicable.
Competing interests
BS is member of the Audentes Therapeutics Board of Scientific and Clinical Advisors. BS has received unrestricted research support, honoraria, and travel funding from Sanofi Genzyme during the past 5 years. BS received honoraria and travel funding as member of the Global Advisory Boards from Biomarin Pharmaceutical, Amicus Therapeutics, and Audentes Therapeutics. DB is a member of the Audentes Therapeutics Board of Scientific and Clinical Advisors. DD is member of the Audentes Therapeutics Board of Scientific and Clinical Advisors. DD has received consulting fees and related expenses from Biomarin, Demeter Therapeutics, Complete Genomics and Illumina during the past 5 years. DD received, through his institution, restricted research grants and related travel funding from Biomarin, Genzyme Sanofi, Hyperion, Alexion and Demeter Therapeutics. EJ and SP are employed by and own stock in Audentes Therapeutics.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Figures
Similar articles
-
The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.Health Technol Assess. 2006 Jul;10(24):iii-iv, ix-136. doi: 10.3310/hta10240. Health Technol Assess. 2006. PMID: 16796930
-
Home treatment for mental health problems: a systematic review.Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150. Health Technol Assess. 2001. PMID: 11532236
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 23;5:CD011535. doi: 10.1002/14651858.CD011535.pub5. PMID: 33871055 Free PMC article. Updated.
-
Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. doi: 10.3310/hta10280. Health Technol Assess. 2006. PMID: 16904047
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068
Cited by
-
Effectiveness of Respiratory Muscle Training in Pompe Disease: A Systematic Review and Meta-Analysis.Children (Basel). 2024 Sep 30;11(10):1209. doi: 10.3390/children11101209. Children (Basel). 2024. PMID: 39457174 Free PMC article. Review.
-
Qualitative interviews to improve patient-reported outcome measures in late-onset Pompe disease: the patient perspective.Orphanet J Rare Dis. 2021 Oct 12;16(1):428. doi: 10.1186/s13023-021-02067-x. Orphanet J Rare Dis. 2021. PMID: 34641935 Free PMC article.
-
Fabry disease pain: patient and preclinical parallels.Pain. 2021 May 1;162(5):1305-1321. doi: 10.1097/j.pain.0000000000002152. Pain. 2021. PMID: 33259456 Free PMC article. Review.
-
Navigating Pompe Disease Assessment: A Comprehensive Scoping Review.Cureus. 2024 Nov 13;16(11):e73593. doi: 10.7759/cureus.73593. eCollection 2024 Nov. Cureus. 2024. PMID: 39677172 Free PMC article.
-
Health-Related Quality of Life and Fatigue in Children with Pompe Disease.J Pediatr Clin Pract. 2024 May 16;14:200116. doi: 10.1016/j.jpedcp.2024.200116. eCollection 2024 Dec. J Pediatr Clin Pract. 2024. PMID: 39950048 Free PMC article.
References
-
- Ebbink BJ, Aarsen FK, van Gelder CM, van den Hout JMP, Weisglas-Kuperus N, Jaeken J, et al. Cognitive outcome of classic infantile Pompe patients receiving enzyme therapy. BMC Musculoskelet Disord. 2013;14(Suppl 2):14. - PubMed
-
- van Gelder CM, van Capelle CI, Ebbink BJ, Moor-van Nugteren I, van den Hout JM, Hakkesteegt MM, et al. Facial-muscle weakness, speech disorders and dysphagia are common in patients with classic infantile Pompe disease treated with enzyme therapy. J Inherit Metab Dis. 2012;35:505–511. doi: 10.1007/s10545-011-9404-7. - DOI - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials